Partners and network - Protein Profiling | Sciomics

Meet us at BioJapan 2023 in Yokohama

Partners

Animal models
		Phenos GmbH Contract research organisation offering services and research expertise to pharmaceutical companies and academia. PHENOS core expertise is the physiological and pathological analysis of mice and rat models. Using its long lasting experience in in-vivo models, Phenos provides its sophisticated expertise in three major areas: Phenotypical analysis of genetic altered mice (e.g. knock-out animals) Preclinical in-vivo evaluation of new drug compounds Identification of new therapeutic strategies of approved drugs Animal models for the study of kidney disease
Cell-Based Assay Services
		Kitos biotech s.r.l.s. Cell-Based Assay Services for Anticancer Drug Discovery Research. The goal of Kitos is to assist customers in discovering innovative therapeutic products in an efficient, cost effective manner. Kitos has a well-equipped facility with cutting-edge technologies and a team of expert and dedicated scientists.
Antibody Specificity Assessment
		Cambridge Protein Arrays Ltd. Cambridge Protein arrays is a CRO offering analysis services based on complex human protein arrays. While the antibody arrays of Sciomics can be used to profile the content of proteins in a sample, recombinant protein arrays are especially useful for the interpretation of binding parameters of antibodies or auto-antibodies to a human proteins. Such arrays provide ultimate insights in the specificity of an antibody and information on eventual cross-binding events.
		PEPperPRINT GmbH Pepperprint offers standard and customized peptide microarrays with their proprietary LASER peptide printing technology which combines high spot densities with content flexibility, production speed and quality in a uniquely cost-effective manner.
Recombinant antibodies
		YUMAB GmbH YUMAB provides tailored solutions for human antibody development and antibody engineering problems. YUMAB provides rapid, large-scale discovery and optimization of human monoclonal antibodies, custom libraries, antibody engineering (e.g., humanization, affinity maturation, various antibody product formats), and custom-made antibodies to difficult antigen targets. YUMAB offers fee-for-service solutions, and attractive and flexible licensing options for diagnostics and therapeutics.
Instrumentation
		DITABIS AG DITABIS entwickelt und fertigt auf der Basis von OEM-Partnerschaften Medizingeräte, Laborgeräte oder Imagingsysteme für Anwendungen in den Bereichen Health Care, Life Science und In-Vitro-Diagnostik.

Research projects

MCDS-Therapy (@MCDS-Therapy)

A Horizon 2020 funded 5-year clinical trial for the repurposing of carbamazepine for the treatment of metaphyseal chondrodysplasia, type Schmid.

> Read our press release

Networks

		BIO Deutschland As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.
		DECHEMA DECHEMA is the expert network for chemical engineering and biotechnology in Germany. As a non-profit professional society we represent these fields in science, industry, politics and the general public. DECHEMA promotes scientific and technical exchange among experts from different disciplines, organisations and generations. We consolidate the know-how of over 5,800 individual and sustaining members.
		BioRN Over the past few years the Rhine-Neckar biotech region has developed into one of Germany’s strongest biotechnology clusters. The cluster is located within a radius of 30 km around the cities of Heidelberg, Mannheim, Darmstadt and Ludwigshafen. It is the most prominent and concentrated biotech cluster in Germany in the fields of personalized medicine and cancer research.
		Technologiepark Heidelberg Heidelberg Technology Park is a science park where major research institutes and global corporations work side by side. The synergies are manifold so that what emerges is a science-based society in which science finds scope for experimentation in industry and scientific research gains new perspectives as a result of international cooperation.
		BioLAGO e.V. BioLAGO is the cross-border health network for life sciences in the four-country-region of Lake Constance (Germany, Switzerland, Austria and Liechtenstein). The network links industry with science for innovations; it promotes knowledge transfer and the foundation of new firms.
		Network Lab-on-a-Chip Technologies Lab-on-a-Chip approaches (short: LoaC) are the combination and integration of several analytical steps of classical and new laboratory analysis on a glass, silicium or plastic chip. The goal is to achiev a high degree of automation as well as the parallelization of many analytical steps (keyword " High Content Screening"). The network focuses on innovative products, production processes and services primarily in the fields of Point-of-care diagnostics systems / Biomarker development Replacement of animal experiments by "organ-on-a-chip" approaches cell analysis / microbiology chip manufacturing

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…

Read more

scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…

scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

Characterise a certain cell type? Cell composition in a certain tissue sample? In-depth profiling of CD-marker expression? Increase your throughput at high sensitivity levels? You aim…

scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay. Features Screen…

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

New article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

Fiedler et al. Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes via PLP Cofactor Mimics (2023) ACS Chem Biol.

New article | Biomarkers for canine mammary neoplasia

| Mai 2023 | New Article: Galadima et al. used the scioCD assay to analyse canine blood samples in the context of mammary neoplasia. The proteins CD20, CD45RA and CD99 were found at altered levels. The findings were validated by Western Blotting and are suggested as novel serum biomarkers.

Galadima et al. Canine Mammary Neoplasia Induces Variations in the Peripheral Blood Levels of CD20, CD45RA, and CD99 (2023) Int. J. Mol. Sci. 24(11)

New article | Microbiota influences chemotherapy in pancreatic cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)

New article | HAPLN1 potentiates peritoneal metastasis in pancreatic cancer

| April 2023 | New Article: Wiedmann et al. identified HAPLN1 as a prognostic marker and as a and as a driver for peritoneal metastasis in pancreatic cancer. Sciomics contributed a plasma protein profiling of a mouse model to support this exciting study.

Wiedmann L et al. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Nature Communications 14,2354 (2023)

New article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19 disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho

over a year ago